Skip to main content

Peer Review reports

From: Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study

Original Submission
20 Jan 2021 Submitted Original manuscript
23 Apr 2021 Author responded Author comments - Lucheng Zhu
Resubmission - Version 2
23 Apr 2021 Submitted Manuscript version 2
Publishing
28 Apr 2021 Editorially accepted
7 May 2021 Article published 10.1186/s12885-021-08266-w

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us